BRPI0814039A2 - Formulações estáveis de derivados de tiadiazol - Google Patents

Formulações estáveis de derivados de tiadiazol

Info

Publication number
BRPI0814039A2
BRPI0814039A2 BRPI0814039A BRPI0814039A BRPI0814039A2 BR PI0814039 A2 BRPI0814039 A2 BR PI0814039A2 BR PI0814039 A BRPI0814039 A BR PI0814039A BR PI0814039 A BRPI0814039 A BR PI0814039A BR PI0814039 A2 BRPI0814039 A2 BR PI0814039A2
Authority
BR
Brazil
Prior art keywords
thiadiazole derivatives
stable formulations
dimethyl
pharmaceutical composition
stable
Prior art date
Application number
BRPI0814039A
Other languages
English (en)
Inventor
Kusano Hiroko
Shyamdeo Mishra Dinesh
Tashiro Yoshikazu
Watanabe Yosuke
Zhuang Hong
Original Assignee
Lilly Co Eli
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39735000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0814039(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Kyowa Hakko Kirin Co Ltd filed Critical Lilly Co Eli
Publication of BRPI0814039A2 publication Critical patent/BRPI0814039A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIÇÃO FARMACÉUTICA E COMPOSIÇÃO FARMACÊUTICA LIOFILIZADA COMPREENDENDO DERIVADOS DE TIADIAZOL. A presente invenção fornece parâmetros de formulação e condições de fabricação para composições farmacêuticas estáveis que compreendem N-(4-(2,2-dimetil-propionil)-(5R)-5-[(2-etilamino-etanossulfonilamino)-metil]-5-fenil-4,5-di-hidro-[1,3,4]tiadiazol-2-il)-2,2-dimetil-propionamida que minimizam a conversão quiral indesejável para a forma enantiomérica S menos ativa.
BRPI0814039A 2007-07-12 2008-07-07 Formulações estáveis de derivados de tiadiazol BRPI0814039A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94926807P 2007-07-12 2007-07-12
PCT/US2008/069301 WO2009009470A1 (en) 2007-07-12 2008-07-07 Stable formulations of thiadiazole derivatiive

Publications (1)

Publication Number Publication Date
BRPI0814039A2 true BRPI0814039A2 (pt) 2017-10-03

Family

ID=39735000

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814039A BRPI0814039A2 (pt) 2007-07-12 2008-07-07 Formulações estáveis de derivados de tiadiazol

Country Status (28)

Country Link
US (1) US8222284B2 (pt)
EP (1) EP2178508B1 (pt)
JP (1) JP4875205B2 (pt)
KR (1) KR101188036B1 (pt)
CN (1) CN101730525A (pt)
AR (1) AR067472A1 (pt)
AU (1) AU2008275258A1 (pt)
BR (1) BRPI0814039A2 (pt)
CA (1) CA2694277C (pt)
CL (1) CL2008001996A1 (pt)
CO (1) CO6270304A2 (pt)
CR (1) CR11210A (pt)
DO (1) DOP2010000004A (pt)
EA (1) EA016861B1 (pt)
EC (1) ECSP109864A (pt)
ES (1) ES2401477T3 (pt)
GT (1) GT201000003A (pt)
HK (1) HK1141238A1 (pt)
IL (1) IL202382A0 (pt)
MA (1) MA31880B1 (pt)
MX (1) MX2010000468A (pt)
NZ (1) NZ581791A (pt)
PE (1) PE20090438A1 (pt)
SV (1) SV2010003449A (pt)
TN (1) TN2010000015A1 (pt)
TW (1) TW200918050A (pt)
UA (1) UA97672C2 (pt)
WO (1) WO2009009470A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8753098B2 (en) 2009-06-26 2014-06-17 Mitsubishi Electric Corporation Refrigerant compressor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100915287B1 (ko) 2001-12-11 2009-09-03 교와 핫꼬 기린 가부시키가이샤 티아디아졸린 유도체
WO2004092147A1 (ja) 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. Ｍ期キネシン阻害剤
JP2006265107A (ja) * 2005-03-22 2006-10-05 Kyowa Hakko Kogyo Co Ltd 緑内障治療剤
EP1867640A4 (en) * 2005-03-22 2010-07-14 Kyowa Hakko Kirin Co Ltd MEANS FOR TREATING SOLID TUMORS
CA2602559A1 (en) * 2005-03-22 2006-09-28 Kyowa Hakko Kogyo Co., Ltd. Agent for treatment of hematopoietic tumor
JP2008150291A (ja) * 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
JP2008137893A (ja) * 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
WO2006137490A1 (ja) * 2005-06-24 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 再狭窄治療剤

Also Published As

Publication number Publication date
ES2401477T3 (es) 2013-04-19
EP2178508A1 (en) 2010-04-28
AR067472A1 (es) 2009-10-14
JP4875205B2 (ja) 2012-02-15
WO2009009470A1 (en) 2009-01-15
TN2010000015A1 (en) 2011-09-26
EA016861B1 (ru) 2012-08-30
US8222284B2 (en) 2012-07-17
KR101188036B1 (ko) 2012-10-05
CA2694277C (en) 2013-04-09
ECSP109864A (es) 2010-03-31
EA201070136A1 (ru) 2010-06-30
IL202382A0 (en) 2010-06-30
CA2694277A1 (en) 2009-01-15
TW200918050A (en) 2009-05-01
UA97672C2 (ru) 2012-03-12
JP2010533190A (ja) 2010-10-21
KR20100029827A (ko) 2010-03-17
EP2178508B1 (en) 2013-02-06
CO6270304A2 (es) 2011-04-20
US20110009458A1 (en) 2011-01-13
MX2010000468A (es) 2010-04-09
PE20090438A1 (es) 2009-04-18
MA31880B1 (fr) 2010-12-01
CR11210A (es) 2010-06-23
HK1141238A1 (en) 2010-11-05
CL2008001996A1 (es) 2009-05-22
CN101730525A (zh) 2010-06-09
SV2010003449A (es) 2010-08-10
AU2008275258A1 (en) 2009-01-15
NZ581791A (en) 2012-03-30
GT201000003A (es) 2012-03-13
DOP2010000004A (es) 2010-03-15

Similar Documents

Publication Publication Date Title
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2007020213A3 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
CU23614B7 (es) Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
JO2962B1 (en) Aminopronic derivatives substituted as niprilicin inhibitors
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
NZ590859A (en) Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases
WO2008027584A3 (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
WO2007089768A3 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
WO2008013838A3 (en) Pyridizinone derivatives
CU20060153A7 (es) Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
PE20090423A1 (es) Compuestos moduladores de sirtuina
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2010114405A3 (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
CA2725933A1 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
WO2006136580A3 (en) 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
WO2009105969A8 (zh) 埃坡霉素类似物、其药物组合物、用途及其制备方法
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009145591A3 (en) Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
PA8717801A1 (es) Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
BR112013031121A2 (pt) composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento
BRPI0814039A2 (pt) Formulações estáveis de derivados de tiadiazol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]